Literature DB >> 23965172

μ opioid receptor agonist-selective regulation of interleukin-4 in T lymphocytes.

Christine Börner1, Sara Lanciotti, Thomas Koch, Volker Höllt, Jürgen Kraus.   

Abstract

Opioids are irreplaceable for the treatment of severe pain. However, opioid-induced immunomodulation affects therapies. Here we report that treatment of human T lymphocytes with the opioids fentanyl, methadone, loperamide and beta-endorphin resulted in a strong induction of the cytokine interleukin-4. In contrast, morphine and buprenorphine induced markedly and significantly lower levels of interleukin-4 mRNA and protein. These findings suggest agonist-biased μ opioid receptor signaling in T cells. In the future, better knowledge about agonist-specific immunomodulatory effects of opioids offers the possibility to select drugs for a therapy with more favorable and/or less detrimental side effects in immune cells.
© 2013.

Entities:  

Keywords:  Biased signaling; Immunomodulation; Interleukin-4; Opioid; T cell; μ-Opioid receptor

Mesh:

Substances:

Year:  2013        PMID: 23965172     DOI: 10.1016/j.jneuroim.2013.07.012

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  25 in total

Review 1.  IL-4, JAK-STAT signaling, and pain.

Authors:  Melanie Busch-Dienstfertig; Sara González-Rodríguez
Journal:  JAKSTAT       Date:  2014-01-02

Review 2.  Influence of opioids on immune function in patients with cancer pain: from bench to bedside.

Authors:  Jason W Boland; A Graham Pockley
Journal:  Br J Pharmacol       Date:  2017-07-23       Impact factor: 8.739

3.  Effects of dietary glutamine supplementation on immune cell polarization and muscle regeneration in diabetic mice with limb ischemia.

Authors:  Man-Hui Pai; Cing-Syuan Lei; Shiau-Tsz Su; Sung-Ling Yeh; Yu-Chen Hou
Journal:  Eur J Nutr       Date:  2019-05-07       Impact factor: 5.614

Review 4.  Opioid Use, Gut Dysbiosis, Inflammation, and the Nervous System.

Authors:  Richa Jalodia; Yaa Fosuah Abu; Mark Ryan Oppenheimer; Bridget Herlihy; Jingjing Meng; Irina Chupikova; Junyi Tao; Nillu Ghosh; Rajib Kumar Dutta; Udhghatri Kolli; Yan Yan; Eridania Valdes; Madhulika Sharma; Umakant Sharma; Shamsudheen Moidunny; Sabita Roy
Journal:  J Neuroimmune Pharmacol       Date:  2022-01-07       Impact factor: 4.147

5.  Effects of Dezocine and Sufentanil on Th1/Th2 Balance in Breast Cancer Patients Undergoing Surgery.

Authors:  Xudong Hu; Bing Luo; Qing Wu; Qingbiao Chen; Penghui Lu; Jie Huang; Xiaoxia Liang; Cheng Ling; Yiqun Li
Journal:  Drug Des Devel Ther       Date:  2021-12-02       Impact factor: 4.162

6.  The impact of prescribed opioids on CD4 cell count recovery among HIV-infected patients newly initiating antiretroviral therapy.

Authors:  E J Edelman; K S Gordon; J P Tate; W C Becker; K Bryant; K Crothers; J R Gaither; C L Gibert; A J Gordon; Bdl Marshall; M C Rodriguez-Barradas; J H Samet; M Skanderson; A C Justice; D A Fiellin
Journal:  HIV Med       Date:  2016-11       Impact factor: 3.180

Review 7.  Opioids and Opioid Maintenance Therapies: Their Impact on Monocyte-Mediated HIV Neuropathogenesis.

Authors:  Matias Jaureguiberry-Bravo; Rebecca Wilson; Loreto Carvallo; Joan W Berman
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

Review 8.  A Review of the Effects of Pain and Analgesia on Immune System Function and Inflammation: Relevance for Preclinical Studies.

Authors:  George J DeMarco; Elizabeth A Nunamaker
Journal:  Comp Med       Date:  2019-12-20       Impact factor: 0.982

Review 9.  The Opioid Epidemic: Impact on Inflammation and Cardiovascular Disease Risk in HIV.

Authors:  Corrilynn O Hileman; Grace A McComsey
Journal:  Curr HIV/AIDS Rep       Date:  2019-10       Impact factor: 5.495

10.  An Investigation into Proteomic Constituents of Cerebrospinal Fluid in Patients with Chronic Peripheral Neuropathic Pain Medicated with Opioids- a Pilot Study.

Authors:  Jonathan Royds; Hilary Cassidy; Melissa J Conroy; Margaret R Dunne; David Matallanas; Joanne Lysaght; Connail McCrory
Journal:  J Neuroimmune Pharmacol       Date:  2020-11-20       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.